Technical Reports on Biotech Stocks -- CytRx, Achaogen, Jaguar Animal, and Illumina

Tuesday, April 18, 2017 General News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, April 18, 2017 /PRNewswire/ --

Focus is shifted on Biotech, an industry that will continue to witness demand

for its products, given an aging population and the increasing prevalence of a wide variety of diseases. As per a Zacks report, strong pipelines, innovative treatments, impressive results, and increased health care spending should support industry growth. Ahead
of today's trading session, recalls the recent performances of CytRx Corp. (NASDAQ: CYTR), Achaogen Inc. (NASDAQ: AKAO), Jaguar Animal Health Inc. (NASDAQ: JAGX), and Illumina Inc. (NASDAQ: ILMN). Download the free research reports on these stocks today:


Los Angeles, California headquartered CytRx Corp.'s shares gained 1.10%, closing Monday's trading session at $0.44. The stock recorded a trading volume of 754,545 shares. The Company's shares have advanced 4.79% in the last month and 18.95% since the start of this year. The stock is trading 3.17% above its 50-day moving average. Additionally, shares of CytRx, which operates as a biopharmaceutical research and development company specializing in oncology, have a Relative Strength Index (RSI) of 54.10. See our free and comprehensive research report on CYTR at:


On Monday, shares in South San Francisco, California headquartered Achaogen Inc. recorded a trading volume of 387,217 shares. The stock rose 1.24%, ending the day at $21.20. The Company's shares have advanced 18.04% in the previous three months and 62.83% on an YTD basis. The stock is trading above its 200-day moving average by 95.16%. Furthermore, shares of Achaogen, which discovers, develops, and commercializes antibacterials to treat multi-drug resistant gram-negative infections in the US, have an RSI of 42.24.

On April 13th, 2017, Achaogen announced seven upcoming presentations on plazomicin at the 27th European Congress of Clinical Microbiology and Infectious Disease. The Company and its collaborators will deliver two oral presentations and five poster presentations at the event, which will be held in Vienna, Austria from April 22nd, 2017 to April 25th, 2017. Achaogen is developing plazomicin, its lead product candidate, to treat serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae. AKAO free research report PDF is just a click away at:

Jaguar Animal  

San Francisco, California headquartered Jaguar Animal Health Inc.'s stock finished the day flat at $0.86 with a total trading volume of 65,880 shares. The Company's shares have advanced 36.51% in the previous three months and 20.11% on an YTD basis. The stock is trading below its 50-day moving average by 13.48%. Additionally, shares of Jaguar Animal Health, which focuses on developing and commercializing gastrointestinal products for companion and production animals, foals, and high value horses, have an RSI of 40.59.

On March 31st, 2017, Jaguar Animal Health and Napo Pharmaceuticals, Inc. announced that they have entered into a definitive merger agreement by unanimous approval by the boards of directors of both companies. As indicated on February 09th, 2017, the financial terms of the merger include an approximate 3-to-1 Napo-to-Jaguar value ratio to calculate relative ownership of the combined entity. Sign up for your complimentary report on JAGX at:


Shares in San Diego, California headquartered Illumina Inc. ended yesterday's session 0.43% higher at $174.42. The stock recorded a trading volume of 586,452 shares. The Company's shares have advanced 9.38% in the last one month, 7.29% over the previous three months, and 36.22% since the start of this year. The stock is trading 4.78% and 12.10% above its 50-day and 200-day moving averages, respectively. Moreover, shares of Illumina, which provides sequencing and array-based solutions for genetic analysis, have an RSI of 60.72.

On March 20th, 2017, research firm Leerink Partners upgraded the Company's stock rating from 'Market Perform' to 'Outperform'.

On April 11th, 2017, Illumina announced that it will issue results for Q1 2017 following the close of market on Tuesday, April 25th, 2017. A conference call will begin at 5:00 pm ET on the same day. The live teleconference can be accessed under the Investor Relations section of the Company's website. Register for free on and download the latest research report on ILMN at:


Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number:  +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store